1371127-04-6

Basic information

• Product Name: 1-(4-Bromo-2-fluoro-benzyl)-4-methanesulfonyl-piperazine
• Synonyms: 1-(4-Bromo-2-fluoro-benzyl)-4-methanesulfonyl-piperazine
• CAS NO: 1371127-04-6
• Molecular Weight: 351.24
• Mol File: 1371127-04-6.mol

Chemical Properties

• CAS DataBase Reference: 1-(4-Bromo-2-fluoro-benzyl)-4-methanesulfonyl-piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Bromo-2-fluoro-benzyl)-4-methanesulfonyl-piperazine(1371127-04-6)
• EPA Substance Registry System: 1-(4-Bromo-2-fluoro-benzyl)-4-methanesulfonyl-piperazine(1371127-04-6)

Safety Data

• Hazardous Substances Data: 1371127-04-6(Hazardous Substances Data)

Upstream product

• 55276-43-2 4-methanesulfonylpiperazine 
• 76283-09-5 4-bromo-2-fluorobenzyl bromide 

Downstream Products

• 1404120-46-2 1-[2-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzyl]-4-methanesulfonyl-piperazine 

Relevant articles and documents

NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.